Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma A/S (NASDAQ: ASND) announced a conference call and live webcast on May 19, 2020, at 4:30 p.m. ET to discuss its Q1 2020 financial results and provide a business update. The call can be accessed via a dial-in number or through the company's website, where a replay will be available for 30 days following the event. Ascendis Pharma focuses on innovative therapies using its TransCon™ platform, with ongoing clinical development in endocrinology and oncology.